In contrast, post-COVID-19 myocarditis shows outcomes similar to conventional myocarditis
THURSDAY, Aug. 29, 2024 (HealthDay News) — Patients with post-COVID-19 mRNA vaccination myocarditis show a lower frequency of cardiovascular complications than those with conventional myocarditis or post-COVID-19 myocarditis at 18 months, according to a study published online Aug. 26 in the Journal of the American Medical Association.
Laura Semenzato, from the French National Agency for the Safety of Medicines and Health Products and French National Health Insurance, and colleagues examined the prognosis and management of post-COVID-19 mRNA vaccination myocarditis compared to other types of myocarditis during 18 months of follow-up. The analysis included 4,635 individuals who were hospitalized for myocarditis, including 558 with postvaccine myocarditis, 298 with post-COVID-19 myocarditis, and 3,779 with conventional myocarditis.
The researchers found that patients with postvaccine myocarditis were younger than those with post-COVID-19 and conventional myocarditis (mean age, 25.9, 31.0, and 28.3 years, respectively) and were more frequently men (84, 67, and 79 percent, respectively). There was a lower standardized incidence of the composite clinical outcome (hospital readmission for myopericarditis, other cardiovascular events, and all-cause death) for patients with postvaccine myocarditis than those with conventional myocarditis (weighted hazard ratio, 0.55; 95 percent confidence interval, 0.36 to 0.86). Individuals with post-COVID-19 myocarditis had similar outcomes to conventional myocarditis (weighted hazard ratio, 1.04; 95 percent confidence interval, 0.70 to 1.52). Postvaccine myocarditis and post-COVID-19 myocarditis showed a similar trend for frequency of medical procedures and drugs prescribed posthospital discharge to that of patients with conventional myocarditis.
“Affected patients, mainly healthy young men, may require medical disease management for up to several months after hospital discharge,” the authors write.
Nearly 3 in 4 Older Adults Express Interest in Vaccine to Prevent Dementia
Updated COVID-19 Shot Beneficial for Those With Autoimmune Rheumatic Disease
Trends Reported in Vaccination Coverage for Adolescents for 2025
AAP Issues Recommendations for Pediatric RSV Vaccination in 2026-2027 Season
4CMenB Vaccine Confers Modest Protection Against Gonorrhea in Teens
AAP Releases Influenza Vaccine Recommendations for All Children 6 Months and Older
Adverse Event Risk Not Up With Same Day COVID-19, Flu Vaccination